Scientists from Harvard University’s Department of Stem Cell and Regenerative Biology have announced significant progress in the treatment of diabetes involving the re-programming of lower stomach cells to act as insulin-producing beta-like cells, meaning the frequent use of insulin injections could be avoided in certain cases. Although researchers have yet to discover a method to apply results yielded from genetically engineered mice to the human body, it is believed that such processes will allow physicians to conduct patient-specific treatments by growing and reproducing insulin-releasing cells from biopsy samples.
Scientists from Harvard University have announced significant progress in the treatment of diabetes involving the re-programming of lower stomach cells to act as insulin-producing beta-like cells, meaning the frequent use of insulin injections could be avoided in certain cases. Although researchers have yet to discover a method to apply results yielded from genetically engineered mice to the human body, it is believed that such processes will allow physicians to conduct patient-specific treatments by growing and reproducing insulin-releasing cells from biopsy samples.